Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book

IJ Pharmaceutical Research

homeHome
play_arrowCurrent Issueformat_list_bulletedAll Issuesformat_indent_increaseIn Presscheck_boxAccepted Manuscripts
searchSearchqr_codeInstructions
bookmarkJournal InformationgroupsEditors & BoardsshareIndexing and Listing Sourceswaterfall_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormemailSupportphoneContact Us
menuAPC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)

1. CDK12 inhibition upregulates ATG7 triggering autophagy via AKT/FOXO3 pathway and enhances anti-PD-1 efficacy in colorectal cancer

- Wu Z. , et al.

2. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications

- Jiang Y. , et al.

3. Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities

- Zabihi M. , et al.

4. CDK9 inhibitors in multiple myeloma: a review of progress and perspectives

- Borowczak J. , et al.

5. Inhibitor of multi-cyclin-dependent kinases (At7519) reduced survival of u937 leukemic cells and enhanced anti-leukemic effect of vincristine: A highlight to cdk inhibition efficacy in acute leukemia

- Moraddahande F.M. , et al.

6. Inhibition of cyclin-dependent kinase (Cdk) decreased survival of nb4 leukemic cells: Proposing a p53-independent sensitivity of leukemic cells to multi-cdks inhibitor at7519

- Pourbagheri-Sigaroodi A. , et al.